RAC 4.32% $1.55 race oncology ltd

Ann: Bisantrene Shows Broad Anti-Cancer Activity in Cancer Cells, page-60

  1. 293 Posts.
    lightbulb Created with Sketch. 410
    I recall you mentioning intrathecal administration a couple years ago. Is this something Race have kept in mind while developing the new formulation?

    Maybe this isn't a relevant question now, but possibly interesting. Unless I misunderstood, your comment back then alluded to bisantrene possibly crossing a leaky BBB without being administered intrathecally. Assuming I read that right, are there different levels of severity in a leaky BBB that would change required dosing? Is it a strategy that is employed with other drugs where a framework could be referenced?
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.